|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | G01N 33/564 |
| (11) | Number of the document | 3250927 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16704525.1 |
| Date of filing the European patent application | 2016-01-28 | |
| (97) | Date of publication of the European application | 2017-12-06 |
| (45) | Date of publication and mention of the grant of the patent | 2020-02-19 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/015344 |
| Date | 2016-01-28 |
| (87) | Number | WO 2016/123329 |
| Date | 2016-08-04 |
| (30) | Number | Date | Country code |
| 201562108914 P | 2015-01-28 | US |
| (72) |
TOWNSEND, Michael, US
SETIADI, Alvernia Francesca, US
STATON, Tracy, US
|
| (73) |
F. Hoffmann-La Roche AG,
Grenzacherstrasse 124, 4070 Basel,
CH
|
| (54) | GENE EXPRESSION MARKERS AND TREATMENT OF MULTIPLE SCLEROSIS |
| GENE EXPRESSION MARKERS AND TREATMENT OF MULTIPLE SCLEROSIS |